CHINA

Beijing Life Science Hub Aims to Accelerate Drug Innovation

Published: Oct. 1, 2025 11:59 a.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

Zhongguancun Life Science Park is fostering a full-chain ecosystem to shorten drug development cycles. Photo: VCG

A sprawling life sciences hub in Beijing is accelerating its drive to turn laboratory breakthroughs into marketable innovative drugs, central to China’s pursuit of global competitiveness in the pharmaceutical sector.

The Zhongguancun Life Science Park, located in the capital’s Changping district, is nurturing an ecosystem that integrates basic research, clinical development, manufacturing and healthcare services. An innovative treatment for hepatitis B and D developed by a company based at the park is already nearing conditional approval.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.

Disclaimer

This is an AI-generated English rendering of original reporting or commentary published by Caixin Media. In the event of any discrepancies, the Chinese version shall prevail.

Share this article

Open WeChat and scan the QR code

DIGEST HUB

Digest Hub

Back

Explore the story in 30 seconds

Zhongguancun Life Science Park in Beijing hosts over 1,000 pharma companies and integrates research, clinical development, and manufacturing to boost China’s pharmaceutical innovation.
A hepatitis B and D drug by Huahui Health Ltd. is expected to receive conditional approval by late 2025 or early 2026; the park fosters breakthroughs in cell/gene therapy, AI health tech, and neuroscience.
The park supports startups with nearly 60 service platforms, contributing to about 5% of China’s CGT clinical trials and 40% of Beijing’s AI medical device certificates.

AI generated, for reference only

Who’s Who

Huahui Health Ltd.: Huahui Health Ltd. is a pharmaceutical firm co-founded by Li Wenhui, a senior researcher at NIBS. Their flagship drug, Libeiweita, a monoclonal antibody for treating hepatitis B and D, is expected to receive conditional marketing approval on the Chinese mainland by late 2025 or early 2026. This drug, based on research from Li's team, has been granted "breakthrough therapy" designation in both China and the U.S.

AI generated, for reference only

GALLERY

: Gallery: China Celebrates Golden Week

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: Why Singapore Sovereign Fund Sues Chinese EV-Maker Nio

00:00

00:00/00:00

MOST POPULAR

1: U.S. Export Ban Wipes Out Nvidia’s China Market, CEO Says

2: China Debuts Ultrafast Oscilloscope in Drive to Break Tech Barriers

3: In Depth: Why Singapore Sovereign Fund Sued Chinese EV-Maker Nio

4: In Depth: Iceland’s President Says China Can Help Scale Its Green Innovations

5: China’s Gold Price Breaks 1,000 Yuan as Regulators Step In